An office building designed by Frank O. Gehry at the Campus of the head office of Novartis Ag in Basel, Switzerland.
Bloomberg | Getty images
Swiss pharmaceutical giant Novartis Friday, said better than expected sales in the fourth quarter, but below his own advice on the section in the full year.
Net sales of the fourth quarter increased by 16% in constant currencies to $ 13.2 billion, compared to the 12.795 billion dollars estimated by analysts in an LSEG survey.
Quarterly adjusted basic operating income amounted to $ 4.86 billion against 4.23 billion dollars expected.
For 2024, net sales increased by 12% in constant currencies to $ 50.32 billion, compared to $ 50.47 billion expected. The basic operating profit by an earlier year increased by 22% to 19.5 billion dollars compared to the planned $ 17.02 billion.
Novartis had increased its results guidelines in 2024 for the third consecutive quarter in October, claiming that it expected that net sales and basic operating income for the growth of “high adolescents” expected to the fact that “adolescents of the high middle” in the middle of adolescence were forecast previously.
The CEO Vas Narasimhan said that the results have marked a positive early signal since the implementation of a strategic overhaul of the company in 2023.
“During our first full year as a company of innovative drugs at stake, Novartis delivered one of the strongest financial performance in our history, sales growth of 12% CC (constant currencies) and income Basic operational of 22% CC, “said Narasimhan in a press release accompanying the results.
“With the momentum that we see in the company, we expect to continue our strong growth in sales with an expansion of margin in 2025 and we remain on the right track to follow our advice at mid-term,” -It declared.
For the future, Narasimhan said that the company focused on the progression of its development pipeline, including more than 30 assets “with the potential to stimulate long -term differentiated growth”.
The company has also described its directives for 2025, providing that net sales will increase from “average to high figure” and the basic operating profit will increase from “double -digit high”.
This is a news and will be updated shortly.
